Glenmark Pharmaceuticals announced today that it received FDA approval for a new drug application (NDA) for Ryaltrais.
Ryaltris, a fixed-dosed, prescription drug product nasal spray treats symptoms of seasonal allergic rhinitis in adults and pediatric patients over 12 years of age in the U.S.
Glenmark’s fully owned subsidiary, Glenmark Specialty S.A. (Switzerland), received the NDA approval for Ryaltris.
Get the full story at our sister site, Drug Delivery Business News.